With key EHA data coming up, Shattuck Labs looks to build on its hypothesis that adding an immune agonism component will transform the SIRPα space

blonca9
May 24, 2024
1 min read

Co-Founder and CEO Taylor Schreiber describes the bi-specific fusion protein construct he is co-inventor of and why he believes it is needed to succeed in the SIRPα (CD47) approach to oncology.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

With key EHA data coming up, Shattuck Labs looks to build on its hypothesis that adding an immune agonism component will transform the SIRPα space

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight